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Abstract
Autologous hematopoietic cell transplantation (AutoHCT) is a potentially curative treatment 
modality for relapsed/refractory Hodgkin lymphoma (HL). However, no large studies have 
evaluated pre-transplant factors predictive of outcomes of AutoHCT in children, adolescents and 
young adults (CAYA, age <30 years). In a retrospective study, we analyzed 606 CAYA patients 
(median age 23 years) with relapsed/refractory HL who underwent AutoHCT between 1995–2010. 
The probabilities of progression free survival (PFS) at 1, 5 and 10 years were 66% (95% CI: 62–
70), 52% (95% CI: 48–57) and 47% (95% CI: 42–51), respectively. Multivariate analysis for PFS 
demonstrated that at the time of AutoHCT patients with Karnofsky/Lansky score ≥90, no 
extranodal involvement and chemosensitive disease had significantly improved PFS. Patients with 
time from diagnosis to first relapse of <1 year had a significantly inferior PFS. A prognostic model 
for PFS was developed that stratified patients into low, intermediate and high-risk groups, 
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predicting for 5-year PFS probabilities of 72% (95% CI: 64–80), 53% (95% CI: 47–59) and 23% 
(95% CI: 9–36), respectively. This large study identifies a group of CAYA patients with relapsed/
refractory HL who are at high risk for progression after AutoHCT. Such patients should be 
targeted for novel therapeutic and/or maintenance approaches post-AutoHCT.
Keywords
CAYA; Autologous transplantation; Hodgkin lymphoma
Introduction
Hodgkin Lymphoma (HL) is the most common cancer in children, adolescents and young 
adults (CAYA) with a peak incidence between the ages of 20 and 341. With the use of 
chemotherapy alone or with the addition of radiotherapy, the overall survival (OS) rate of 
newly diagnosed HL in CAYA is approximately 80–90%1,2. However, a subset of CAYA 
patients with HL have refractory disease to first line therapies or experience disease 
relapse2. For these patients, conventional salvage therapies, followed by autologous 
hematopoietic cell transplantation (AutoHCT) is often considered the standard of care. Even 
with the addition of AutoHCT, many patients will not achieve long-term remission3. The 
outlook for such patients remains poor. A small prospective study by Baker et al., 
demonstrated that the 5-year probability of failure-free survival in CAYA patients with 
relapsed/refractory HL following AutoHCT was only 31%4.
Various factors influence the outcome of patients with relapsed/refractory HL. Long-term 
survival of patients with HL is age dependent; patients <15 years and 15–29 years have 
better long-term survival probability than do patients 30–44 years old. Patients older than 45 
years of age tend to fare less well5. In a handful of small CAYA AutoHCT studies the 
following have been shown to be associated with inferior outcomes: time to relapse6–8, 
primary refractory disease4,6, 9–12, response to salvage chemotherapy7,9,11–13, extranodal 
involvement10,14, mediastinal mass10 and high serum lactate dehydrogenase (LDH) levels at 
the time of relapse4. While the findings in these studies are compelling, their small sample 
sizes and inconsistent evaluation methodology make the above prognostic indicators 
difficult to generalize across larger CAYA population.
In adult patients with HL, various prognostic models have identified and validated various 
disease and patient-specific variables present either at diagnosis15 or prior to AutoHCT 16–18 
that are associated with inferior outcomes. These identified predictive factors in older adults 
may not be applicable to CAYA, as older adults potentially have more co-morbidity. 
However, differences in disease biology, if any, among CAYA and older adults are yet to be 
elucidated.
To date, there are no published large-scale studies looking at risk factors or prognostic 
indicators in CAYA patients with relapsed/refractory HL undergoing AutoHCT. Thus, in 
this Center for International Bone Marrow Transplant Research (CIBMTR) analysis, we 
evaluated various risk factors that might be prognostic in CAYA patients undergoing 
AutoHCT for relapsed/refractory HL.
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The CIBMTR is a working group of more than 450 transplantation centers worldwide that 
contribute detailed data on HCTs to a statistical center at the Medical College of Wisconsin. 
Centers report HCTs consecutively with compliance monitored by on-site audits. Patients 
are followed longitudinally with yearly follow-up. Observational studies by the CIBMTR 
are performed in compliance with federal regulations with ongoing review by the 
institutional review board of the Medical College of Wisconsin.
Patients
There is no universally accepted definition of AYA. The National Cancer Institute 
Adolescent and Young Adult Oncology Progress Review Group include patients from 15 to 
39 years of age. However, Surveillance, Epidemiology, and End Results (SEER) and 
Children’s Oncology Group’s Adolescents and Young Adults Committees define AYA as 
15 to 29 years of age19. In the current study we defined AYA as patients from 15–29 years 
old.
CAYA (age <30 years) with a histologically proven diagnosis of relapsed or refractory HL, 
undergoing first peripheral blood AutoHCT reported to the CIBMTR between 1995 and 
2010 were included in this study. Patients achieving a complete remission (CR) with 1st line 
therapy and then undergoing upfront AutoHCT consolidation (n=23), without any evidence 
of relapsed or refractory disease before transplantation were excluded. Subjects undergoing 
a planned tandem HCT (tandem AutoHCT, n=14; or AutoHCT followed by tandem 
allogeneic HCT, n=1), those with nodular lymphocyte predominant HL (n=6), and human 
immunodeficiency virus positive cases (n=10) were also excluded.
Definitions and Endpoints
To assess disease status at AutoHCT, (chemo-) sensitive disease on CIBMTR forms is 
define as ≥50% reduction in greatest diameter of all disease sites, with no new sites of 
disease on radiographic assessment, while (chemo-) resistant disease is defined as <50% 
reduction in the diameter of all disease sites, or development of new disease sites. Positron 
emission tomography (PET scan) data were not available for response assessment during the 
era of this study, the CIBMTR database.
Primary outcomes in this study were non-relapse mortality (NRM), progression/relapse, 
progression-free survival (PFS) and OS. NRM was defined as death without evidence of 
disease progression/relapse; relapse was considered a competing event. Progression/relapse 
was defined as progressive disease after AutoHCT or disease recurrence after a CR; NRM 
was considered a competing event. For PFS, a patient was considered a treatment failure at 
the time of progression/relapse or death from any cause. Patients alive without evidence of 
disease relapse or progression were censored at last follow-up. The OS was defined as the 
interval from the date of AutoHCT to the date of death or last follow-up.
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Probabilities of PFS and OS were calculated using the Kaplan-Meier estimator. Probabilities 
of NRM, disease progression/relapse, and hematopoietic recovery were calculated using 
cumulative incidence curves to accommodate for competing events20. Associations among 
patient, disease and transplant-related variables and outcomes of interest were analyzed 
using Cox proportional hazards regression. A stepwise selection was used to identify 
covariates that influenced outcomes. Covariates with a p<0.01 were considered significant. 
The proportionality assumption for Cox regression was tested by adding a time-dependent 
covariate for each risk factor and each outcome. Interactions among significant variables 
were examined. Results are expressed as relative risk (RR) of occurrence of the event. The 
variables considered in multivariate analysis are shown in Table 1.
Prognostic Model for PFS
To develop a prognostic model of PFS in the CAYA population post-AutoHCT a Cox 
regression method was used to identify potential risk factors associated with treatment 
failure (failure event of PFS). This was done using a forward stepwise model with p<0.01 to 
enter and remove contributing factors from the model. Results were then confirmed using a 
backward elimination procedure and then a forward selection. The risk factors considered in 
the model-building procedure are shown in Table 1. Based on the final multivariate model 
and relative risk of significant prognostic factors, each factor was assigned a score of 1. All 
statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results
Patient Characteristics
Between 1995 and 2010, 606 CAYA with the median age of 23 years (3–29 years) were 
included in this study. Patient characteristics are described in Table 2. Briefly, the majority 
of patients in this analysis were Caucasian/white (77%), the most common histological 
subtype was nodular sclerosis (77%), at diagnosis disease stage was I–II in 50% and III–IV 
in 48%, while 53% patients had B-symptoms and 32% patients had extranodal involvement 
at the time of diagnosis. The median number of lines of therapy before AutoHCT was two, 
and 60% of patients received first line ABVD (doxorubicin, bleomycin, vinblastine, 
dacarbazine) or ABVD-like chemotherapy with or without radiation. Extranodal 
involvement at AutoHCT was reported in 18% patients. The majority of the patients (79%) 
had chemosensitive disease prior to AutoHCT. The most commonly utilized conditioning 
regimen (67%) was BEAM (BCNU, etoposide, cytarabine and melphalan).
Univariate Outcomes
For the total cohort, the probabilities of NRM at 1, 3, 5 and 10 years were 6% (95% CI: 4–
8), 6% (4–8), 7% (95% CI: 5–9) and 9% (95% CI: 6–12), respectively (Figure 1A). The 
probabilities of disease progression/relapse at 1, 3, 5 and 10 years were 28% (95% CI: 24–
32), 38% (95% CI: 34–42), 41% (95% CI: 37–45) and 45 % (95% CI: 40–49) (Figure 1B). 
The probabilities of PFS at 1, 3, 5 and 10 years were 66 % (95% CI: 62–70), 57% (95% CI: 
53–61), 52% (95% CI: 48–57) and 47% (95% CI: 42–51), respectively (Figure 1C). The 
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probability for OS were 87% (95% CI: 84–89), 74% (95% CI: 70–78), 68% (95% CI: 63–
71) and 58% (95% CI: 53–63), respectively (Figure 1D).
Multivariate Outcomes
On multivariate analysis for NRM, the single significant factor associated with higher NRM 
was utilization of non-ABVD regimens as a first line therapy compared to ABVD/ABVD-
like regimens (RR=2.47; 95% CI=1.32–4.62: p=0.004) [Table 3]. Multivariate analysis for 
disease progression/relapse demonstrated that patients with Karnofsky/Lansky performance 
score (KPS/LPS) <90 (RR=1.46; 95% CI=1.08–1.98: p=0.01), utilization of CBV 
(cyclophosphamide, BCNU and etoposide) conditioning regimen (RR=1.72; 95% CI=1.21–
2.45: p=0.003), presence of extranodal involvement at AutoHCT (RR=1.67; 95% CI=1.23–
2.29: p=0.001) and chemoresistant disease (RR=1.75; 95% CI=1.29–2.36; p=0.0003) were 
associated with a higher risk of relapse/progression post-AutoHCT, while time from 
diagnosis to first relapse (TDFR) interval of ≥1 year was associated with a reduced risk of 
progression/relapse (RR= 0.65; 95% CI=0.48–0.88: p=0.006).
Patients who had a KPS/LPS <90 (RR–1.45; 95% CI=1.10–1.92: p=0.008), extranodal 
involvement at AutoHCT (RR=1.59; 95% CI=1.19–2.12: p=0.001) and chemoresistant 
disease (RR=1.84; 95% CI=1.40–2.42: p<0.0001) had a higher risk of therapy failure (i.e. 
inferior PFS). Patients with TDFR interval of ≥1 year had a lower risk of therapy failure (i.e. 
superior PFS) (RR=0.71; 95% CI=0.54–0.93: p=0.01) [Table 3].
On multivariate analysis a higher risk of mortality (inferior OS) was associated with first 
line therapy with non-ABVD compared to ABVD/ABVD-like regimens (RR=1.64; 95% 
CI=1.21–2.22: p=0.001), the presence of extranodal involvement at AutoHCT (RR=1.81; 
95% CI=1.29–2.52: p=0.0005), and chemoresistance disease (RR=2.27; 95% CI=1.64–3.13: 
p=<0.0001). In contrast, patients with a TDFR interval of ≥ 1 year had a lower risk of 
mortality (i.e. superior OS) (RR=0.62; 95% CI=0.44–0.86: p=0.004) [Table 3].
Prognostic Model for PFS
The four significant adverse prognostic factors, each assigned a score of 1, included in the 
final model were (i) KPS/LPS <90%, (ii) TDFR of <1 year, (iii) extranodal involvement at 
AutoHCT and (iv) chemoresistant disease at AutoHCT. The score for any individual patient 
using the 4 significant prognostic factors, ranged from 0 to 4. Table 4 summarizes the 
prognostic model’s performance. Distribution of patients by total risk score was as follows: 
126 patients had a total risk score of 0 (reference category), 192 patients had a total risk 
score of 1 (RR=1.81 range, 1.25 to 2.62), 129 patients had a total risk score of 2 (RR=2.11 
range, 1.42 to 3.13), 38 patients had a total risk score of 3 (RR=3.92 range, 2.42 to 6.36) and 
4 patients had a total risk score of 4 (RR=11.33 range, 4.03 to 31.82).
Based on the range of RR and the distribution of patients across the total risk score 
categories, we classified each patient into three prognostic risk groups: low-risk group (score 
= 0), intermediate-risk group (score = 1 or 2), or high-risk group (score = 3 or 4). Statistical 
significance was reached when we compared the PFS between low and intermediate group 
(p=0.0002), low and high risk group (p<0.0001) and intermediate and high risk group 
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(p<0.0001). The 3-year PFS probabilities for the low, intermediate and high risk groups are 
75% (95% CI=67–82), 56% (95% CI=51–62) and 29% (95% CI=15–43), respectively. The 
probability for 5-year PFS were 72% (95% CI: 64–80), 53% (95% CI: 47–59) and 23% 
(95% CI: 9–36) respectively, for the three prognostic groups (Figure 2).
Cause of Death and Secondary Malignancies
At a median follow-up of 64 months 209 patients were no longer alive. The primary causes 
of death post-AutoHCT were recurrent HL (N=154, 74% of all deaths), organ failure (N=12, 
6%), second malignancy (N=4, 2%), infection (N=7, 3%) or other/indeterminate (N=32, 
15%). At a median follow-up of 64 months, 16 patients (3%) developed secondary 
malignancies. New malignancies reported included one case each of basal cell carcinoma, 
breast cancer, chronic lymphocytic leukemia, prostate cancer, oligodendroglioma, 
carcinoma of the pleural cavity and two cases each of acute myeloid leukemia, 
myelodysplastic syndrome and thyroid cancer. There were 3 cases of genitourinary cancer 
and one missing second malignancy subtype.
Discussion
To our knowledge, this is the largest study describing the outcomes of CAYA with relapsed/
refractory HL following AutoHCT. For the first time, we propose a prognostic model 
specifically for CAYA patients undergoing AutoHCT for relapsed/refractory HL. Previous 
HL models included older patients and therefore may not be as relevant for the CAYA 
population. Our large CAYA data set enabled us to develop a simple-to-use, clinically 
relevant prognostic model identifying 4 risk factors easily available at the time of AutoHCT.
Due to the improvement in upfront treatment strategies for newly diagnosed HL, the 
outcome for patients with HL has improved such that approximately 80% of HL patients 
become long-term survivors now 21. However, for those who have relapsed or refractory 
disease, outcomes are variable, with some patients achieving long-term remission after 
AutoHCT and others responding poorly. Improved prognostic tools are needed to identify 
such high-risk patients. Various prognostic factors have been identified from a series of 
clinical studies that are frequently small. Such studies often lack statistical power to 
definitively define prognostic factors, which has led to a lack of consistency and consensus 
across studies2,22. Because of this, accurately determining risk of treatment failure for 
CAYA patients undergoing AutoHCT remains a challenge, which makes identification of 
patients suitable for intensified or investigational therapies difficult. CIBMTR data are 
uniformly collected with rigorous quality control and has large number of patients with 
contemporary and generalizable data. Hence, in this large analysis we were able to identify 
the prognostic factors associated with poor outcomes in CAYA patients with HL post-
AutoHCT.
Previously published studies with small number of patients (highest n=70)12, prognostic 
factors that have been studied in CAYA are primary refractory disease (3–10 year OS/EFS/
DFS: 35–47%)6,9–12, early relapse within one year of diagnosis (3–10 years OS/DFS: 34–
67%)6–8, poor response to salvage therapy (2–5 year OS/DFS/EFS: 6–30%)7,9,11–13, 
extranodal involvement at relapse (8 year EFS-7%)14 and B-symptoms at relapse (2yr 
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OS-27%)9. In our large CAYA study, the probabilities of PFS at 1 and 5 years following 
AutoHCT were 66% and 52%, respectively. Patients with TDFR of <1 year, extranodal 
involvement at AutoHCT, chemoresistant disease and KPS/LPS <90 at the time of 
AutoHCT all had inferior PFS. Of interest, according to our analysis, age, time from 
diagnosis to AutoHCT, disease stage at diagnosis and relapse, B-symptoms, bulky disease at 
the time of AutoHCT, LDH at the time of AutoHCT, number of chemotherapy regimens 
prior to AutoHCT and radiation therapy prior to AutoHCT were not associated with PFS.
Our analysis of 606 HL CAYA patients, with relapse/refractory HL who were treated with 
AutoHCT found three prognostic factors consistently associated with relapse/progression, 
PFS and OS. These prognostic indicators were as follows: TDFR <1 year, extranodal 
involvement at relapse and chemoresistant disease at the time of AutoHCT.
This study has limitations of being retrospective, patients were reported to the CIBMTR 
over the period of 15 years, and PET scan data were not collected. Over that last decade PET 
scan has emerged as an important prognostic factor in adults with relapsed HL as patients 
with negative PET study prior to AutoHCT have been shown to have superior 
outcomes23–24. With regard to our study, PET data was not uniformly captured during the 
era in question. We therefore were not able to determine the impact of PET status pre-
AutoHCT. Our data suggest that the extent of exposure to specific cytotoxic chemotherapy 
agents during salvage therapy does not directly correlate with PFS. However, knowing that 
PET-avid disease prior to AutoHCT has been associated with inferior outcomes in other 
studies23–24, reasonable efforts should be made to achieve PET negative status prior to 
AutoHCT, whether that be using conventional therapy25 or novel therapies such as 
brentuximab vedotin26 or bendamustine27.
Various conditioning regimens have been utilized for patients with relapsed HL. In our 
study BEAM, busulfan-based and CBV were the most frequently utilized regimens. In 
multivariate analysis, the incidence of NRM did not differ across various conditioning 
regimens. We did find, however, that compared to BEAM, CBV conditioning was 
associated with a higher-risk of progression/relapse (RR-1.72, p=0.002). Similar results 
were reported by William et al28. NRM in our study was 6% and 7% at 1 and 5 years 
respectively which is comparable to the studies published in adults with relapsed/refractory 
HL receiving AutoHCT 29–31. However, incidence of NRM in a prospective COG study that 
utilized CBV conditioning regimen for AutoHCT in children with relapsed/refractory 
lymphoma was 13% (5/38)7. In the current study, utilization of non-ABVD regimens as a 
first line therapy was associated with higher NRM and lower OS. It is plausible that patients 
treated with a more intensive first line non-ABVD regimen have less risk of primary relapse. 
However, few patients who relapse experience higher NRM resulting in lower OS.
The CAYA population with HL is a unique and challenging, despite excellent outcomes, 
still includes a subset of patients whose survival is unacceptably low. Because they are 
younger at diagnosis, they are at risk of long-term complications and significant morbidity 
later in life as a result of disease treatment. The prognostic model developed in our study 
identifies a group of high-risk patients, who have suboptimal outcomes despite AutoHCT 
salvage. Investigation of novel conditioning approaches or post-AutoHCT therapies e.g. 
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maintenance brentuximab vedotin26, reduced-intensity allogeneic HCT35, cellular therapy36 
or incorporation of PD-1 inhibitors37, for these CAYA with poor prognosis is warranted.
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Autologous hematopoietic cell transplantation outcomes for children, adolescents and young 
adults with Hodgkin lymphoma
1A: Non-relapse related mortality.
1B: Progression/relapse.
1C: Progressions free survival.
1D: Overall survival.
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Prognostic model predicting progression free survival for children, adolescents and young 
adults with Hodgkin lymphoma with low, intermediate and high risk scores [low vs. 
intermediate score (p=0.0002), low vs. high score (p<0.0001) and intermediate vs. high 
score (p<0.0001)].
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Table 1
Variables tested in Cox proportional hazards regression models for relapse/progression, non-relapse mortality, 
overall survival and progression free survival.
Patient-related:
Age at transplant, years: continuous; and <21 vs. ≥21 year
Gender: Male vs. Female
Karnofsky or Lansky performance status ≥90 vs. <90 vs. missing
Race: Caucasian/White vs. Black vs. others
Disease-related:
Histology: nodular sclerosis vs. lymphocyte-rich vs. mixed cellularity vs. lymphocyte depleted vs. HL, not otherwise specified
Time from diagnosis to first relapse after 1st line therapy: continuous & <1 year (including refractory to first line) vs. ≥1 year
Time from diagnosis to transplant: continuous
Disease stage at diagnosis: I/II vs. III/IV
B symptoms: No vs. Yes
LDH at AutoHCT: normal vs. high
Number of lines of therapy prior to transplant: continuous & <3 vs. ≥3 lines
First line therapy: ABVD or ABVD-like [±Radiation] vs. All other regimens [± Radiation] vs. Unknown/Missing
Extranodal involvement at AutoHCT: No vs. Yes
Bulky disease at AutoHCT: No vs. Yes
Prior history of radiation therapy: Yes vs. No
Disease status at Auto: sensitive vs. resistant
Transplant-related:
Conditioning regimen: BEAM vs. CBV vs. other
Year of transplantation: continuous and 1995–2000 vs. 2001–2005 vs. 2006–2010
HL-Hodgkin lymphoma, ABVD-doxorubicin, bleomycin, vinblastine, dacarbazine, AutoHCT-Autologous hematopoietic cell transplant, BEAM-
BCNU, etoposide, cytarabine, melphalan, CBV-cyclophosphamide, carmustine, etoposide.
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Table 2
Characteristics of <30 years old patients who underwent AutoHCT for relapsed/refractory HL from 1995–
2010 reported to the CIBMTR.
Variable N (%)
Total number of patients 606
Age at AutoHCT, years
 Median 23 (3–29)
 <21 208 (34)
 ≥21 398 (66)
Male Sex 332 (55)
KPS/LPS
 <90% 124 (20)
 90–100% 454 (75)
Race
 Caucasian/White 464 (77)
 Black 57 ( 9)
 Asian/Pacific Islander 14 ( 2)
 Hispanic 58 (10)
 Others 13 ( 2)
HL subtype
 Lymphocyte-rich 26 ( 4)
 Nodular sclerosis 468 (77)
 Mixed cellularity 57 ( 9)
 Lymphocyte depleted 10 ( 2)
 Not specified 45 ( 7)
Time from diagnosis to first relapse (TDFR) pre-AutoHCT, months
 Median (range) 22 (5–229)
 <12 (including patients refractory to 1st line therapy) 322 (53)
 ≥12 213 (35)
 Missing 71 (12)
Time from diagnosis to AutoHCT, months (range) 19 (3–238)
Disease stage at diagnosis
 I–II 300 (50)
 III–IV 293 (48)
 Unknown 13 ( 2)
B-Symptoms at diagnosis
 Present 323 (53)
Elevated LDH concentration prior to AutoHCT 158 (26)
Number of chemotherapy lines 2 (1–5)
First line chemotherapy
ABVD or ABVD-like ± radiation 361 (60)
BEACOPP-like ± radiation 23 ( 4)
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Variable N (%)
CHOP-like ± radiation 15 ( 2)
MOPP/ABV(±D) or COPP/ABV (±D) Hybrid ± radiation 88 (15)
COPP or MOPP ± radiation 32 ( 5)
Stanford V 2 (<1)
Radiation alone or other chemotherapy ± radiation 85 ( 14)
Bone marrow involvement at diagnosis 40 ( 7)
Bone marrow involvement at AutoHCT 9 ( 1)
Total number of patients 606
Extranodal involvement at diagnosis 196 (32)
Extranodal involvement at AutoHCT 107 (18)
Bulky disease at AutoHCT 73 (12)
Radiation prior to AutoHCT 276 (46)
Chemosensitive disease prior to AutoHCT
 Sensitive 479 (79)
 Resistant 113 (19)
 Missing (Untreated relapse/unknown (n=11) included) 14 ( 2)
Disease status prior to AutoHCT
 PIF sensitive 90 (15)
 PIF resistant 53 ( 9)
 CR1 35 ( 6)
 Relapsed sensitive 209 (34)
  Relapsed resistant 60 (10)
 CR2+ 145 (24)
 Untreated relapse/unknown 11 ( 2)
 Missing 3 (<1)
Conditioning regimens
 TBI-based 33 ( 5)
 BEAM and similar 406 (67)
 CBV or similar 77 (13)
 BuMEL/BuCy 42 ( 7)
 Others* 48 ( 8)
 Year of AutoHCT
 1995–2000 325 (54)
 2001–2005 127 (21)
 2006–2010 154 (25)
 Planned radiation post-AutoHCT 183 (30)
 Median follow-up of survivors median (range) 64 (4–216)
ABVD-like=include omission of either bleomycin or dacarbazine from standard ABVD or substitution of doxorubicin with epirubicin. PIF 
resistant= primary induction failure sensitive resistant: never in CR but with stable or progressive disease on treatment; PIF sensitive=primary 
induction failure sensitive: never in CR but with partial remission.
HL-Hodgkin lymphoma, KPS/LS-Karnofsky/Lansky performance status, TDFR-Time from diagnosis to first relapse, LDH- lactate dehydrogenase, 
ABVD- doxorubicin, bleomycin, vinblastine, dacarbazine, BEACOPP-Bleomycin, etoposide, Adriamycin, cyclophosphamide, oncovin, 
procarbazine, prednisone, COPP- , cyclophosphamide, oncovin, procarbazine, prednisone, MOPP-mechlorethamine, oncovin, procarbazine, 
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prednisone CHOP- Cyclophosphamide, daunorubicin, oncovin, prednisone AutoHCT- Autologous hematopoietic cell transplant, TBI-total body 
irradiation, BEAM- BCNU, etoposide, cytarabine, melphalan, CBV- cyclophosphamide, carmustine, etoposide. BUMEL/BuCy- busulfan-
melphalan/busulfan-cyclophosphamide
*
Bu alone (n=1), Bu+Thio (n=1), Carboplatin+Mito+Thio (n=4), Carboplatin+Thio (n=3), Carboplatin+VP16+ Ifos (n=5), Carboplatin
+VP16+LPAM (n=8), Cy+Carboplatin+Thio (n=5), CY+mito/nitro+thio (n=2), Cy+Thio (n=6), Cy+Thio+Mesna (n=2), LPAM alone (n=8), 
LPAM+Mito (n=1), VP16 (n=1), unknown (n=1)
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